IOVS Circulation Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2007;48:1212-1218.)
© 2007 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.06-0757
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Figure
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhong, L.
Right arrow Articles by Ng, Y.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhong, L.
Right arrow Articles by Ng, Y.-S.

Erythropoietin Promotes Survival of Retinal Ganglion Cells in DBA/2J Glaucoma Mice

Lichun Zhong,1 John Bradley,1 William Schubert,1 Ednan Ahmed,2 Anthony P. Adamis,1 David T. Shima,1 Gregory S. Robinson,1 and Yin-Shan Ng1

1From (OSI) Eyetech, Inc., Lexington, Massachusetts; and the 2Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.

PURPOSE. Retinal ganglion cell (RGC) loss occurs in response to increased intraocular pressure (IOP) and/or retinal ischemia in glaucoma and leads to impairment of vision. This study was undertaken to test the efficacy of erythropoietin (EPO) in providing neuroprotection to RGCs in vivo.

METHODS. The neuroprotective effects of EPO were studied in the DBA/2J mouse model of glaucoma. Mice were intraperitoneally injected with control substances or various doses of EPO, starting at the age of 6 months and continuing for an additional 2, 4, or 6 months. RGCs were labeled retrogradely by a gold tracer. IOP was measured with a microelectric-mechanical system, and EPO receptor (EPOR) expression was detected by immunohistochemistry. Axonal death in the optic nerve was quantified by para-phenylenediamine staining, and a complete blood count system was used to measure the number of erythrocytes.

RESULTS. In DBA/2J mice, the average number of viable RGCs significantly decreased from 4 months to 10 months, with an inverse correlation between the number of dead optic nerve axons and viable RGCs. Treatment with EPO at doses of 3000, 6000, and 12,000 U/kg body weight per week all prevented significant RGC loss, compared with untreated DBA/2J control animals. EPO effects were similar to those of memantine, a known neuroprotective agent. IOP, in contrast, was unchanged by both EPO and memantine. Finally, EPOR was expressed in the RGC layer in both DBA/2J and C57BL/6J mice.

CONCLUSIONS. EPO promoted RGC survival in DBA/2J glaucomatous mice without affecting IOP. These results suggest that EPO may be a potential therapeutic neuroprotectant in glaucoma.




This article has been cited by other articles:


Home page
 Diabetes CareHome page
M. Garcia-Ramirez, C. Hernandez, and R. Simo
Expression of Erythropoietin and Its Receptor in the Human Retina: A comparative study of diabetic and nondiabetic subjects
Diabetes Care, June 1, 2008; 31(6): 1189 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. Bosco, D. M. Inman, M. R. Steele, G. Wu, I. Soto, N. Marsh-Armstrong, W. C. Hubbard, D. J. Calkins, P. J. Horner, and M. L. Vetter
Reduced Retina Microglial Activation and Improved Optic Nerve Integrity with Minocycline Treatment in the DBA/2J Mouse Model of Glaucoma
Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1437 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
B. P. Buckingham, D. M. Inman, W. Lambert, E. Oglesby, D. J. Calkins, M. R. Steele, M. L. Vetter, N. Marsh-Armstrong, and P. J. Horner
Progressive Ganglion Cell Degeneration Precedes Neuronal Loss in a Mouse Model of Glaucoma
J. Neurosci., March 12, 2008; 28(11): 2735 - 2744.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. Scholz, T. Buder, S. Seeber, E. Adamek, C.-M. Becker, and E. Lutjen-Drecoll
Dependency of Intraocular Pressure Elevation and Glaucomatous Changes in DBA/2J and DBA/2J-Rj Mice
Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 613 - 621.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J. Zhang, Y. Wu, Y. Jin, F. Ji, S. H. Sinclair, Y. Luo, G. Xu, L. Lu, W. Dai, M. Yanoff, et al.
Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells in Early Diabetes
Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 732 - 742.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
I. Soto, E. Oglesby, B. P. Buckingham, J. L. Son, E. D. O. Roberson, M. R. Steele, D. M. Inman, M. L. Vetter, P. J. Horner, and N. Marsh-Armstrong
Retinal Ganglion Cells Downregulate Gene Expression and Lose Their Axons within the Optic Nerve Head in a Mouse Glaucoma Model
J. Neurosci., January 9, 2008; 28(2): 548 - 561.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. Saleh, M. Nagaraju, and V. Porciatti
Longitudinal Evaluation of Retinal Ganglion Cell Function and IOP in the DBA/2J Mouse Model of Glaucoma
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4564 - 4572.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Nishijima, Y.-S. Ng, L. Zhong, J. Bradley, W. Schubert, N. Jo, J. Akita, S. J. Samuelsson, G. S. Robinson, A. P. Adamis, et al.
Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury
Am. J. Pathol., July 1, 2007; 171(1): 53 - 67.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Association for Research in Vision and Ophthalmology